5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasmActive, not recruitingPhase 22026-09-29NCT05768711
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesUntreated Myelodysplastic SyndromeActive, not recruitingPhase 1 / Phase 22026-08-11NCT05782127
A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in FranceNewborn Screening Programmes for Rare DiseasesRecruitingNot stated2026-06-17NCT06875089
Venetoclax in Patients With MDS or AML in Relapse After AHSCTacute myeloid leukemia, myelodysplastic syndromeActive, not recruitingPhase 1 / Phase 22026-03-12NCT05226455
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaB-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-02-19NCT04842877